5 min
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D Answers from the Lab
-
- Médecine
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
(00:32) Could you provide us with a little bit of information about yourself and your background?
(01:18) Can you start with a brief overview of the assay?
(02:13) Which patients should have this testing and when should it be performed?
(03:21) Are there alternative test options available and how do those compare with the folate receptor alpha assay?
(03:57) How are the results used in patient care?
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
(00:32) Could you provide us with a little bit of information about yourself and your background?
(01:18) Can you start with a brief overview of the assay?
(02:13) Which patients should have this testing and when should it be performed?
(03:21) Are there alternative test options available and how do those compare with the folate receptor alpha assay?
(03:57) How are the results used in patient care?
5 min